Quality: The Gold Standard for CDMOs - No Exceptions, No Compromises

By: Jody Chastain, CEO, The Ritedose Corporation

In today’s hyper-competitive pharmaceutical landscape, innovation, speed-to-market and cost control usually take the spotlight when selecting a contract development and manufacturing organization (CDMO). However, underneath all those metrics, a single truth remains: if quality fails, so does everything else.

For pharmaceutical developers, quality isn’t a box to simply check. It’s the foundation that supports every milestone. And when it comes to choosing a CDMO partner, quality shouldn’t just be part of the conversation - it should be the conversation.

However, most pharmaceutical developers choosing a CDMO aren’t placing an emphasis on quality when selecting their manufacturing partner. In fact, according to the ISR 2022 Small Molecule Drug Product CDMO Benchmark report, only a mere 13% of respondents cited a CDMO’s quality track record as their top priority when selecting a partner.

In an industry where patient safety, regulatory compliance, and product integrity hang in the balance, quality should never be an afterthought. It really needs to be the first thought. The fact that so few developers rank it as their leading consideration reveals a concerning gap - one that can lead to delayed approvals, costly mistakes, and potential risks to patients.

When it comes to manufacturing, our company’s mantra is to always do things the right way. We follow industry guidelines and unapologetically set the standards high. Upholding these standards and continually improving is non-negotiable for us at Ritedose.

I believe it’s very simple. The gold standard for CDMOs is this:

• Transparency in documentation, deviation management and communication
• Investments in talent and technology that anticipates and prevents issues
• Quality team members embedded throughout the entire organization at every touch point
• Fostering a culture of excellence

Forward-Thinking, Pre-Emptive Measures

Rigorous quality control testing and analysis at every stage of production help us detect and address risks early. Quality assurance goes beyond documentation and protocols, it involves thoughtful, forward-thinking, pre-emptive measures that ensure consistency and reliability - minimizing unexpected challenges. Additionally, maintaining strong quality protocols accelerates time to market, reduces contamination risks, and provides patients with medications they can trust. This also fosters ongoing customer relationships that are built on a strong reputation for excellence, where commitment to high standards fosters confidence and trust.

Beyond Processes and Documentation – Fostering a Culture of Excellence

Quality isn’t just a department - it’s a team-wide mindset. A CDMO must foster a culture of excellence amongst all employees. It’s why at Ritedose, one of our values is “insist on perfection.” Our team members are to daily ask themselves if they are insisting on perfection, and if not, what do they need to do to fix it. But employees need a “why”.

This is why we make a concerted effort to continually reinforce our “why” with our employees. Our “why” is the patients we serve. We place pictures of our employee’s loved ones who use our manufactured medications throughout our facilities as a constant and steady reminder of why we care so much that our work is quality. The best CDMOs know that a top-down culture of quality reduces risk, accelerates regulatory approvals and protects reputations. We hire for it; we train for it; we celebrate it at every turn.

Prioritizing Strategic Investments

CDMOs that prioritize strategic investments in their infrastructure and capabilities are also better positioned to scale, meet growing demand, and support their clients effectively. At Ritedose, we are dedicated to investing in cutting-edge technologies and robust quality management systems. While premium quality may require greater investment, it provides the assurance that products will meet the most stringent standards.

Choosing a CDMO is one of the most consequential decisions a pharmaceutical developer will make. The real ROI isn’t just lower costs or faster timelines - it’s peace of mind - for the developer and patients.